New Neurons: The Future of Regenerative Therapy
During this webinar, learn about the present state and future directions of therapies designed to regenerate neural tissue lost in stroke.
Upon completion of this activity, participants should be able to:
- Review the state of stem cell therapy for ischemic stroke.
- Discuss the potential of virus-mediated astrocyte to neuron conversion in stroke.
- Discuss the machine-human interface in the recovery of function.
The AANS designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the AANS. This educational activity does not endorse one particular type of instrumentation, nor is it intended to dictate an exclusive course of management. It presents one of numerous recognized methods of clinical practice for consideration by physicians for incorporation into their practices. Variations of practice taking into account the needs of the individual patient, resources, and limitations unique to the institution or type of practice may be appropriate. Disclosure about patient confidentiality, standards of care, or course of management does not imply endorsement or disapproval of products.
Please note: It is recognized that the use of non-FDA approved devices is described in some of the published material, but these techniques are often the standard of care and may be of value to the patients we serve.
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the AANS must ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. In accordance with the ACCME’s Standards for Commercial Support, the AANS is required to disclose to the activity audience the relevant financial relationships of the planners, faculty and any other individual in a position to control content of this activity.
Please find the relevant financial relationships disclosed below for all individuals in control of content. All conflicts of interest have been resolved in accordance with ACCME Standards for Commercial Support.
|Gary K. Steinberg, MD, PhD, FAANS||Grants/Research Support – NIH NINDS, California Institute for Regenerative Medicine (CIRM), Qool Therapeutics Consultant Fees – Peter Lazic US, Inc., Medtronic, SanBio Stock Shareholder (purchased direct) - Peter Lazic US, Inc., Neurosave|
Planners, faculty and any other individuals in control of content not listed have indicated that they have no relevant financial relationships to disclose for this activity.
Scott Douglas Simon, MD, FAANS
The AANS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AANS designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity was published in 5-19-2020. Credit may be obtained until 5-19-2023.
|Access Date||Quiz Result||Score||Actions|